Article Text

PDF
CRMP5 antibodies found in a patient with limbic encephalitis and myasthenia gravis
  1. S E Monstad,
  2. J K Nøstbakken,
  3. C A Vedeler
  1. Department of Clinical Medicine, University of Bergen and Department of Neurology, Haukeland University Hospital, Bergen, Norway
  1. Professor C A Vedeler, Department of Clinical Medicine, University of Bergen, Norway; christian.vedeler{at}helse-bergen.no

Abstract

Collapsin response mediator protein 5 (CRMP5) antibodies are often associated with thymoma or small cell lung cancer and paraneoplastic syndromes such as limbic encephalitis (LE). A patient is described with myasthenia gravis who, following thymectomy and immunosuppression, acquired a viral infection and developed LE and increased levels of serum CRMP5 antibodies. The cognitive symptoms improved and CRMP5 antibody levels decreased after plasma exchange, suggesting that CRMP5 antibodies may have contributed to the development of LE.

Statistics from Altmetric.com

Footnotes

  • Funding: The study was supported by grants from the University of Bergen and Haukeland University Hospital, Norway.

  • Competing interests: None.

  • Patient consent: Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.